Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study
Objective: As patients with increased human epidermal growth factor receptor (HER2) overexpression are more likely to benefit from trastuzumab treatment, the accuracy of HER2 receptor status in breast cancer patients is significant for appropriate disease management. However, this assessment is not...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2018-07-01
|
| Series: | European Journal of Breast Health |
| Subjects: | |
| Online Access: |
http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/mmunohistochemical-her2-status-evaluation-in-breas/42039
|
| _version_ | 1797910422327656448 |
|---|---|
| author | Tülay Canda Ekrem Yavuz Necmettin Özdemir Sennur İlvan Serpil Sak Dizbay Merih Güray Durak Sıtkı Tuzlalı Osman Zekioğlu Atakan Demir Handan Onur Kasım Üstündağ Burçe Göktaş |
| author_facet | Tülay Canda Ekrem Yavuz Necmettin Özdemir Sennur İlvan Serpil Sak Dizbay Merih Güray Durak Sıtkı Tuzlalı Osman Zekioğlu Atakan Demir Handan Onur Kasım Üstündağ Burçe Göktaş |
| author_sort | Tülay Canda |
| collection | DOAJ |
| description | Objective: As patients with increased human epidermal growth factor receptor (HER2) overexpression are more likely to benefit from trastuzumab treatment, the accuracy of HER2 receptor status in breast cancer patients is significant for appropriate disease management. However, this assessment is not harmonized and results may be highly variable between centers. The aim of this study was to investigate the degree of interlaboratory variability in the results of HER2 expression reported by 5 participating centers and to assess the concordance between these centers and a reference laboratory.Materials and Methods: A total of 30 breast cancer samples were tested and scored for HER2 expression using immunohistochemical method in 5 centers from Turkey and in a reference laboratory from Netherlands (Academic Medical Center, Amsterdam). All the participating centers had an experience of more than 10 years regarding the HER2 testing. The results were compared both among the centers and with the reference laboratory.Results: When the concordance of participating centers and the reference laboratory was evaluated regarding negative (0-1+), equivocal 2(+) and positive 3(+) classification of HER2 immunostaining, the highest concordance was found in Center-A, and the lowest in Center-C (Kendall's tau-b concordance coefficient 0.911 and 0.724, respectively). The concordance of the centers with reference laboratory was 80.0% both in equivocal and positive samples, while it increased up to 91.8% in negative samples.Conclusions: This study showed that in general there is sufficiently good agreement between the reference laboratory and the participating centers for immunohistochemical HER2 assessment. |
| first_indexed | 2024-04-10T11:24:05Z |
| format | Article |
| id | doaj.art-0ce1214ddc9f43f8aa5dbf4aada0330f |
| institution | Directory Open Access Journal |
| issn | 2587-0831 |
| language | English |
| last_indexed | 2024-04-10T11:24:05Z |
| publishDate | 2018-07-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | European Journal of Breast Health |
| spelling | doaj.art-0ce1214ddc9f43f8aa5dbf4aada0330f2023-02-15T16:18:30ZengGalenos Publishing HouseEuropean Journal of Breast Health2587-08312018-07-0114316016510.5152/ejbh.2018.396113049054Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance StudyTülay Canda0Ekrem Yavuz1Necmettin Özdemir2Sennur İlvan3Serpil Sak Dizbay4Merih Güray Durak5Sıtkı Tuzlalı6Osman Zekioğlu7Atakan Demir8Handan Onur9Kasım Üstündağ10Burçe Göktaş11 Department of Pathology, Dokuz Eylül University School of Medicine, İzmir, Turkey Department of Pathology, İstanbul University, İstanbul School of Medicine, İstanbul, Turkey Department of Pathology, Ege University School of Medicine, İzmir, Turkey Department of Pathology, İstanbul University, Cerrahpaşa School of Medicine, İstanbul, Turkey Department of Pathology, Ankara University School of Medicine, Ankara, Turkey Department of Pathology, Dokuz Eylül University School of Medicine, İzmir, Turkey Department of Pathology, İstanbul University, İstanbul School of Medicine, İstanbul, Turkey Department of Pathology, Ege University School of Medicine, İzmir, Turkey Department of Pathology, İstanbul University, Cerrahpaşa School of Medicine, İstanbul, Turkey Department of Pathology, Ankara University School of Medicine, Ankara, Turkey Clinical Research, Roche Preparations San. Inc., İstanbul, Turkey Clinical Research, Roche Preparations San. Inc., İstanbul, Turkey Objective: As patients with increased human epidermal growth factor receptor (HER2) overexpression are more likely to benefit from trastuzumab treatment, the accuracy of HER2 receptor status in breast cancer patients is significant for appropriate disease management. However, this assessment is not harmonized and results may be highly variable between centers. The aim of this study was to investigate the degree of interlaboratory variability in the results of HER2 expression reported by 5 participating centers and to assess the concordance between these centers and a reference laboratory.Materials and Methods: A total of 30 breast cancer samples were tested and scored for HER2 expression using immunohistochemical method in 5 centers from Turkey and in a reference laboratory from Netherlands (Academic Medical Center, Amsterdam). All the participating centers had an experience of more than 10 years regarding the HER2 testing. The results were compared both among the centers and with the reference laboratory.Results: When the concordance of participating centers and the reference laboratory was evaluated regarding negative (0-1+), equivocal 2(+) and positive 3(+) classification of HER2 immunostaining, the highest concordance was found in Center-A, and the lowest in Center-C (Kendall's tau-b concordance coefficient 0.911 and 0.724, respectively). The concordance of the centers with reference laboratory was 80.0% both in equivocal and positive samples, while it increased up to 91.8% in negative samples.Conclusions: This study showed that in general there is sufficiently good agreement between the reference laboratory and the participating centers for immunohistochemical HER2 assessment. http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/mmunohistochemical-her2-status-evaluation-in-breas/42039 immunohistochemistrybreast cancerdiagnosisher2 |
| spellingShingle | Tülay Canda Ekrem Yavuz Necmettin Özdemir Sennur İlvan Serpil Sak Dizbay Merih Güray Durak Sıtkı Tuzlalı Osman Zekioğlu Atakan Demir Handan Onur Kasım Üstündağ Burçe Göktaş Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study European Journal of Breast Health immunohistochemistry breast cancer diagnosis her2 |
| title | Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study |
| title_full | Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study |
| title_fullStr | Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study |
| title_full_unstemmed | Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study |
| title_short | Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study |
| title_sort | immunohistochemical her2 status evaluation in breast cancer pathology samples a multicenter parallel design concordance study |
| topic | immunohistochemistry breast cancer diagnosis her2 |
| url |
http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/mmunohistochemical-her2-status-evaluation-in-breas/42039
|
| work_keys_str_mv | AT tulaycanda immunohistochemicalher2statusevaluationinbreastcancerpathologysamplesamulticenterparalleldesignconcordancestudy AT ekremyavuz immunohistochemicalher2statusevaluationinbreastcancerpathologysamplesamulticenterparalleldesignconcordancestudy AT necmettinozdemir immunohistochemicalher2statusevaluationinbreastcancerpathologysamplesamulticenterparalleldesignconcordancestudy AT sennurilvan immunohistochemicalher2statusevaluationinbreastcancerpathologysamplesamulticenterparalleldesignconcordancestudy AT serpilsakdizbay immunohistochemicalher2statusevaluationinbreastcancerpathologysamplesamulticenterparalleldesignconcordancestudy AT merihguraydurak immunohistochemicalher2statusevaluationinbreastcancerpathologysamplesamulticenterparalleldesignconcordancestudy AT sıtkıtuzlalı immunohistochemicalher2statusevaluationinbreastcancerpathologysamplesamulticenterparalleldesignconcordancestudy AT osmanzekioglu immunohistochemicalher2statusevaluationinbreastcancerpathologysamplesamulticenterparalleldesignconcordancestudy AT atakandemir immunohistochemicalher2statusevaluationinbreastcancerpathologysamplesamulticenterparalleldesignconcordancestudy AT handanonur immunohistochemicalher2statusevaluationinbreastcancerpathologysamplesamulticenterparalleldesignconcordancestudy AT kasımustundag immunohistochemicalher2statusevaluationinbreastcancerpathologysamplesamulticenterparalleldesignconcordancestudy AT burcegoktas immunohistochemicalher2statusevaluationinbreastcancerpathologysamplesamulticenterparalleldesignconcordancestudy |